Gilead Sciences, Inc. (NASDAQ: GILD) is one of the. The company announced that the US FDA approved Yeztugo ® (lenacapavir), ...

吉利德科学（Gilead Sciences）与Kymera ...

研究表明，在服用PrEP药物的人群中，能够坚持每日服药的比例只有约30-50%。现实中的依从性问题严重影响了PrEP的预防效果。来那帕韦的半年注射给药方式，很大程度上解决了这个问题,不仅可以提高用药依从性，还能减轻使用者的心理负担。

吉利德科学公司（Gilead Sciences，NASDAQ:GILD）董事长兼首席执行官丹尼尔·奥戴（Daniel ...

As Gilead Sciences gets underway with the key launch of its twice-yearly pre-exposure prophylaxis (PrEP) HIV med, the company ...

Shares of Gilead Sciences Inc. rallied 2.83% to $110.67 Friday, on what proved to be an all-around great trading session for ...

Gilead Sciences, Inc. (NASDAQ: GILD) and Kymera Therapeutics, Inc. (NASDAQ: KYMR), today announced that they have entered ...

Gilead Sciences has entered into an option and license deal with Kymera Therapeutics to support the development and sales of ...

See the latest Gilead Sciences GILD stock price (NASDAQ: GILD), related news, valuation, dividends and more to help you make your investing decisions.

Gilead Sciences (GILD) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some ...

Gilead Sciences Inc. closed 11.48% below its 52-week high of $119.96, which the company reached on March 10th.